Title:
THERAPEUTIC AGENT CONTAINING ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS AND IMMUNE CELLS AND USE THEREFOR
Document Type and Number:
WIPO Patent Application WO/2020/192684
Kind Code:
A1
Abstract:
Provided are a therapeutic agent containing isolated recombinant oncolytic adenovirus and immune cells and a use therefor. The therapeutic agent contains: a first composition containing a first active substance located in a first pharmaceutically acceptable carrier, said first active substance containing an isolated conditionally replicating recombinant oncolytic adenovirus into which a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells has been integrated; and a second composition containing a second active substance located in a second pharmaceutically acceptable carrier, the second active substance containing T cell receptor modified immune cells or chimeric antigen receptor modified immune cells. The present therapeutic agent may be used in treating tumors and/or cancer.
More Like This:
Inventors:
SHENG JIPO (CN)
HOU YAFEI (US)
WENG LIHONG (CN)
TAN XIANKUI (CN)
DONG XIAOMING (CN)
WANG XUE (CN)
HU FANG (CN)
HOU YAFEI (US)
WENG LIHONG (CN)
TAN XIANKUI (CN)
DONG XIAOMING (CN)
WANG XUE (CN)
HU FANG (CN)
Application Number:
PCT/CN2020/081090
Publication Date:
October 01, 2020
Filing Date:
March 25, 2020
Export Citation:
Assignee:
HANGZHOU CONVERD CO LTD (CN)
SYNIMMUNE INC (US)
SYNIMMUNE INC (US)
International Classes:
A61K35/768; A61P35/00; C12N5/0783; C12N7/01; C12N15/861
Domestic Patent References:
| WO2018195427A2 | 2018-10-25 | |||
| WO2018023025A1 | 2018-02-01 | |||
| WO2018159991A1 | 2018-09-07 |
Foreign References:
| CN109576231A | 2019-04-05 | |||
| CN107073089A | 2017-08-18 | |||
| CN108913690A | 2018-11-30 | |||
| CN108753715A | 2018-11-06 | |||
| CN109045289A | 2018-12-21 |
Other References:
TANOUE K ET AL.: "Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors", CANCER RESEARCH, vol. 77, 15 April 2017 (2017-04-15), pages 2040 - 2051, XP055384740, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-16-1577
SHAW AR ET AL.: "Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells Against Metastatic Head and Neck Cancer", MOLECULAR THERAPY, vol. 25, no. 11, 1 November 2017 (2017-11-01), XP009506306, ISSN: 1525-0024, DOI: 10.1016/j.ymthe.2017.09.010
WING A ET AL.: "Improving CART- Cell Therapy of Solid Tumors With Oncolytic Virus-Driven Production of a Bispecific T- cell Engager", CANCER IMMUNOLOGY RESEARCH, vol. 6, no. 5, 31 May 2018 (2018-05-31), XP009517684, ISSN: 2326-6074, DOI: 10.1158/2326-6066.CIR-17-0314
SHAW AR ET AL.: "Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells Against Metastatic Head and Neck Cancer", MOLECULAR THERAPY, vol. 25, no. 11, 1 November 2017 (2017-11-01), XP009506306, ISSN: 1525-0024, DOI: 10.1016/j.ymthe.2017.09.010
WING A ET AL.: "Improving CART- Cell Therapy of Solid Tumors With Oncolytic Virus-Driven Production of a Bispecific T- cell Engager", CANCER IMMUNOLOGY RESEARCH, vol. 6, no. 5, 31 May 2018 (2018-05-31), XP009517684, ISSN: 2326-6074, DOI: 10.1158/2326-6066.CIR-17-0314
Attorney, Agent or Firm:
TEE&HOWE INTELLECTUAL PROPERTY ATTORNEYS (CN)
Download PDF: